IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by First Trust Advisors LP

First Trust Advisors LP boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 59,966 shares of the medical research company's stock after buying an additional 7,969 shares during the period. First Trust Advisors LP's holdings in IQVIA were worth $11,784,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of IQV. Howard Capital Management Inc. boosted its holdings in IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after acquiring an additional 54 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in shares of IQVIA by 1.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock worth $1,068,000 after acquiring an additional 56 shares during the last quarter. Cypress Wealth Services LLC increased its position in IQVIA by 4.8% in the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock worth $244,000 after purchasing an additional 57 shares during the period. Harbor Investment Advisory LLC grew its position in shares of IQVIA by 4.7% during the 4th quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock worth $253,000 after buying an additional 58 shares during the period. Finally, Magnolia Capital Advisors LLC raised its position in shares of IQVIA by 2.9% during the 4th quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company's stock valued at $516,000 after acquiring an additional 74 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on IQV shares. Morgan Stanley raised their price objective on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Mizuho decreased their target price on shares of IQVIA from $242.00 to $210.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Robert W. Baird dropped their price target on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. Truist Financial cut their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Finally, HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and an average target price of $237.62.

IQVIA Trading Up 1.1 %

Shares of IQV traded up $1.65 during mid-day trading on Wednesday, reaching $155.10. 2,232,397 shares of the company's stock traded hands, compared to its average volume of 1,428,904. The stock has a market cap of $27.35 billion, a P/E ratio of 20.68, a P/E/G ratio of 1.99 and a beta of 1.46. The stock's 50-day moving average is $169.86 and its two-hundred day moving average is $192.72. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.